IP Library Granted Patent US 8,916,527
Granted Patent B2
US 8,916,527 · App. 13/832,869 · Granted Dec 23, 2014

Antibiotic macrocycle compounds and methods of manufacture and use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,916,527
App. No.
13/832,869
Granted
Dec 23, 2014
Kind
B2
Abstract

The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically GI infections caused by toxin producing strains of Clostridium difficile ( C. difficile ) and Clostridium perfringens ( C. perfringens ).

Claims (13)

1. A method of treating a Clostridium difficile infection in a subject in need thereof comprising administering to the subject a composition comprising a therapeutically effective amount of a compound of Formula II:

in free form or in the form of a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the infection is a gastrointestinal infection.

3. The method of claim 2 , wherein the subject is human.

4. The method of claim 3 , wherein the subject has previously been treated for a Clostridium difficile infection with a compound other than Formula II.

5. The method of claim 3 , wherein the subject is suffering from Clostridium difficile associated diarrhea.

6. The method of claim 3 , wherein the subject is suffering from pseudo-membranous colitis.

7. The method of claim 6 , wherein the subject is suffering from antibiotic associated diarrhea.

8. The method of claim 2 , wherein the route of administration is oral.

9. The method of claim 1 , wherein the dosage is 0.1 milligrams to 200 milligrams per kilogram of the subject's body weight.

10. The method of claim 1 , wherein the dosage is 1 milligram to 200 milligrams per kilogram of the subject's body weight.

11. The method of claim 1 , wherein the dosage is 1 milligram to 100 milligrams per kilogram of the subject's body weight.

12. The method of claim 1 , wherein the dosage is 2 milligrams to 50 milligrams per kilogram of the subject's body weight.

Assignments (1)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →